Glyceroniosomes for enhanced intestinal absorption of hydrochlorothiazide and lisinopril in their fixed dose combination.
Fixed dose combination
Glyceroniosome
Hydrochlorothiazide
In situ intestinal perfusion
Lisinopril
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
24
03
2024
accepted:
30
09
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
The objective was to investigate the effect of co-administration of hydrochlorothiazide and lisinopril as fixed dose combination on their intestinal absorption. The scope was extended to enhance intestinal absorption of both drugs. In situ rabbit intestinal absorption through the duodenum and jejuno-ileum was used to monitor membrane permeability of both drugs when perfused alone or in combination. Niosomes containing glycerols (glyceroniosomes) were loaded with both drugs. Glyceroniosomes comprised Span 60 or Tween 40 in combination with cholesterol and glycerol were prepared by bath sonication. Glyceroniosomes were characterized with respect to vesicle size, drug entrapment efficiency and were examined using transmission electron microscope (TEM). The prepared vesicles were nanosized spherical vesicles with average size of 202.4 nm and 108.8 nm for span free and span containing glyceroniosomes, respectively. The recorded Zeta potential values suggested good stability of the prepared formulations. Intestinal absorption studies reflected incomplete absorption of hydrocholothiazide and lisinopril correlating with their categorization as class IV and III drugs, respectively. Co-perfusion of both drugs reduced the intestinal absorption of lisinopril. Simultaneous encapsulation in glyceroniosomes enhanced the intestinal absorption of both drugs. Tween based systems were more efficient. The study introduced glyceroniosomes as carriers of simultaneous delivery of hydrochlorothiazide and lisinopril.
Identifiants
pubmed: 39424875
doi: 10.1038/s41598-024-74986-1
pii: 10.1038/s41598-024-74986-1
doi:
Substances chimiques
Lisinopril
E7199S1YWR
Hydrochlorothiazide
0J48LPH2TH
Glycerol
PDC6A3C0OX
Liposomes
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24499Informations de copyright
© 2024. The Author(s).
Références
Desai, D., Wang, J., Wen, H., Li, X. & Timmins, P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm. Dev. Technol. 18(6), 1265–1276. https://doi.org/10.3109/10837450.2012.660699 (2013).
doi: 10.3109/10837450.2012.660699
pubmed: 22339230
Gautam, C. S. & Saha, L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br. J. Clin. Pharmacol. 65(5), 795–796. https://doi.org/10.1111/j.1365-2125.2007.03089.x (2008).
doi: 10.1111/j.1365-2125.2007.03089.x
pubmed: 18294326
pmcid: 2432494
Bangalore, S., Kamalakkannan, G., Parkar, S. & Messerli, F. H. Fixed dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120(8), 713–719. https://doi.org/10.1016/j.amjmed.2006.08.033 (2007).
doi: 10.1016/j.amjmed.2006.08.033
pubmed: 17679131
Moon, C. & Oh, E. Rationale and strategies for formulation development of oral fixed dose combination drug products. J. Pharm. Investig. 46, 615–631. https://doi.org/10.1007/s40005-016-0286-4 (2016).
doi: 10.1007/s40005-016-0286-4
Hiremath, P. S., Bhonsle, S. A., Thumma, S. & Vemulapalli, V. Recent patents on oral combination drug delivery and formulations. Recent Pat. Drug Deliv. Formul. 5(1), 52–60. https://doi.org/10.2174/187221111794109475 (2011).
doi: 10.2174/187221111794109475
pubmed: 21143126
Jagdale, S. C., Suryawanshi, V. M., Pandya, S. V., Kuchekar, B. S. & Chabukswar, A. R. Development of press-coated, floating- pulsatile drug delivery of lisinopril. Sci. Pharm. 82(2), 423–440. https://doi.org/10.3797/scipharm.1301-27 (2014).
doi: 10.3797/scipharm.1301-27
pubmed: 24959410
pmcid: 4065132
Lancaster, S. G. & Todd, P. A. Lisinopril: A preliminary review of its pharmacodynamics, pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 35(6), 646–669. https://doi.org/10.2165/00003495-198835060-00003 (1988).
doi: 10.2165/00003495-198835060-00003
pubmed: 2844497
Amidon, G. L., Lennernas, H., Shah, V. P. & Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413–420. https://doi.org/10.1023/A:1016212804288 (1995).
doi: 10.1023/A:1016212804288
pubmed: 7617530
Reddy, B. K. & Karunakar, A. P. Biopharmaceutics classification system: A regulatory approach. Dissolution Technol. 18, 3–37. https://doi.org/10.14227/DT180111P31 (2011).
doi: 10.14227/DT180111P31
Patel, R. B. et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J. Pharm. Sci. 73(3), 359–361. https://doi.org/10.1002/jps.2600730317 (1984).
doi: 10.1002/jps.2600730317
pubmed: 6716243
Armayor, G. M. & Lopez, L. M. Lisinopril: A new angiotensin-converting enzyme inhibitor. Drug Intell. Clin. Pharm. 22(5), 365–372. https://doi.org/10.1177/106002808802200501 (1988).
doi: 10.1177/106002808802200501
pubmed: 2839326
Bezalel, S., Mahlab-Guri, K., Asher, I., Werner, B. & Sthoeger, Z. M. Angiotensin-converting enzyme inhibitor-induced angioedema. Am. J. Med. 128(2), 120–125. https://doi.org/10.1016/j.amjmed.2014.07.011 (2015).
doi: 10.1016/j.amjmed.2014.07.011
pubmed: 25058867
Beermann, B. Pharmacokinetics of lisinopril. Am. J. Med. 85(3B), 25–30. https://doi.org/10.1016/0002-9343(88)90346-4 (1988).
doi: 10.1016/0002-9343(88)90346-4
pubmed: 2844083
Sultan, A. A., El-Gizawy, S. A., Osman, M. A. & El Maghraby, G. M. Colloidal carriers for extended absorption window of furosemide. J. Pharm. Pharmacol. 68(3), 324–332. https://doi.org/10.1111/jphp.12516 (2016).
doi: 10.1111/jphp.12516
pubmed: 26773855
Fayed, N. D., Arafa, M. F., Essa, E. A. & El Maghraby, G. M. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption. J. Drug Deliv. Sci. Technol. 74, 103587. https://doi.org/10.1016/j.jddst.2022.103587 (2022).
doi: 10.1016/j.jddst.2022.103587
pubmed: 35845293
pmcid: 9272570
Uner, M. & Yener, G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2(3), 289–300 (2007).
Yin, Y. M. et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J. Control Release. 140(2), 86–94. https://doi.org/10.1016/j.jconrel.2009.08.015 (2009).
doi: 10.1016/j.jconrel.2009.08.015
pubmed: 19709639
Kim, H., Kim, Y. & Lee, J. Liposomal formulations for enhanced lymphatic drug delivery. Asian J. Pharm. Sci. 8(2), 96–103. https://doi.org/10.1016/j.ajps.2013.07.012 (2013).
doi: 10.1016/j.ajps.2013.07.012
Arzani, G., Haeri, A., Daeihamed, M., Bakhtiari-Kaboutaraki, H. & Dadashzadeh, S. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int. J. Nanomed. 10, 4797–4813. https://doi.org/10.2147/IJN.S84703 (2015).
doi: 10.2147/IJN.S84703
Lee, M. K. Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. Pharmaceutics. 12(3), 264. https://doi.org/10.3390/pharmaceutics12030264 (2020).
doi: 10.3390/pharmaceutics12030264
pubmed: 32183185
pmcid: 7151102
Guan, P. et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int. J. Nanomed. 6, 965–974. https://doi.org/10.2147/IJN.S19259 (2011).
doi: 10.2147/IJN.S19259
Manca, M. L. et al. Glycerosomes: A new tool for effective dermal and transdermal drug delivery. Int. J. Pharm. 455(1–2), 66–74. https://doi.org/10.1016/j.ijpharm.2013.07.060 (2013).
doi: 10.1016/j.ijpharm.2013.07.060
pubmed: 23911913
Naguib, M. J., Salah, S., Abdel Halim, S. A. & Badr-Eldin, S. M. Investigating the potential of utilizing glycerosomes as a novel vesicular platform for enhancing intranasal delivery of lacidipine. Int. J. Pharm. 582, 119302. https://doi.org/10.1016/j.ijpharm.2020.119302 (2020).
doi: 10.1016/j.ijpharm.2020.119302
pubmed: 32276091
Fayed, N. D., Goda, A. E., Essa, E. A. & El Maghraby, G. M. Chitosan-encapsulated niosomes for enhanced oral delivery of atorvastatin. J. Drug Deliv. Sci. Technol. 66(8), 102866. https://doi.org/10.1016/j.jddst.2021.102866 (2021).
doi: 10.1016/j.jddst.2021.102866
Gandra, S. Rosuvastatin calcium proniosome powder: a novel approach to improve intestinal absorption and bioavailability. Asian J. Pharm. Clin. Res. 13(12), 148–156 (2020).
doi: 10.22159/ajpcr.2020.v13i12.39585
Validation of analytical procedures: methodology. ICH Harmonized Tripartite Guidline. (1996).
El Maghraby, G. M., Osman, M. A. & Ahmed, A. A. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm. J. 23(1), 67–74. https://doi.org/10.1016/j.jsps.2014.05.001 (2014).
doi: 10.1016/j.jsps.2014.05.001
pubmed: 25685045
pmcid: 4310994
Sultan, A. A., El-Gizawy, S. A., Osman, M. A. & El Maghraby, G. M. Peceosomes for oral delivery of glibenclamide: In vitro in situ correlation. J. Drug Deliv. Sci. Technol. 41, 303–309. https://doi.org/10.1016/j.jddst.2017.08.003 (2017).
doi: 10.1016/j.jddst.2017.08.003
Riad, L. E. & Sawchuk, R. J. Absorptive clearance of carbamazepine and selected metabolites in rabbit intestine. Pharm. Res. 8, 1050–1055. https://doi.org/10.1023/A:1015817426713 (1991).
doi: 10.1023/A:1015817426713
pubmed: 1924159
Osman, M. A., El Maghraby, G. M. & Hedaya, M. A. Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site dependent absorptive clearance. Biopharm. Drug Dispos. 27(2), 93–102. https://doi.org/10.1002/bdd.487 (2006).
doi: 10.1002/bdd.487
pubmed: 16369998
Komiya, I., Park, J. Y., Kamani, A., Ho, N. F. H. & Higuchi, W. I. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int. J. Pharm. 4(3), 249–262. https://doi.org/10.1016/0378-5173(80)90140-4 (1980).
doi: 10.1016/0378-5173(80)90140-4
Gan, G., Cartier, L. L., Huang, Y., Yang, Z. & Sawchuk, R. J. Intestinal absorption and presystemic disposition of the prokinetic agent, EM574 in rabbit. J. Pharm. Sci. 91(1), 217–228. https://doi.org/10.1002/jps.10002 (2002).
doi: 10.1002/jps.10002
pubmed: 11782911
Sultan, A. A., El-Gizawy, S. A., Osman, M. A. & El Maghraby, G. M. Niosomes for oral delivery of nateglinide: In situ in vivo correlation. J. Liposome Res. 28(3), 209–217. https://doi.org/10.1080/08982104.2017.1343835 (2017).
doi: 10.1080/08982104.2017.1343835
pubmed: 28618876
Abdelaziz, A. A., Elbanna, T. E., Sonbol, F. I., Gamaleldin, N. M. & El Maghraby, G. M. Optimization of niosomes for enhanced antibacterial activity and reduced bacterial resistance: in vitro and in vivo evaluation. Expert Opin. Drug Deliv. 12, 163–180. https://doi.org/10.1517/17425247.2014.942639 (2015).
doi: 10.1517/17425247.2014.942639
pubmed: 25135453
Junyaprasert, V. B., Teeranachaideekul, V. & Supaperm, T. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech. 9(3), 851–859. https://doi.org/10.1208/s12249-008-9121-1 (2008).
doi: 10.1208/s12249-008-9121-1
pubmed: 18636334
pmcid: 2977041
Sultan, A. A., El Nashar, N. F., Ashmawy, S. M. & El Maghraby, G. M. Cubosomes for enhancing intestinal absorption of fexofenadine hydrochloride: In situ and in vivo investigation. Int. J. Nanomed. 17, 3543–3560. https://doi.org/10.2147/IJN.S370235 (2022).
doi: 10.2147/IJN.S370235
Sultan, A. A., Saad, G. A. & El Maghraby, G. M. Permeation enhancers loaded bilosomes for improved intestinal absorption and cytotoxic activity of doxorubicin. Int. J. Pharm. 630, 122427. https://doi.org/10.1016/j.ijpharm.2022.122427 (2023).
doi: 10.1016/j.ijpharm.2022.122427
pubmed: 36435504
El Maghraby, G. M., Williamsb, A. C. & Barry, B. W. Drug interaction and location in liposomes: correlation with polar surface areas. Int. J. Pharm. 292(1–2), 179–185. https://doi.org/10.1016/j.ijpharm.2004.11.037 (2005).
doi: 10.1016/j.ijpharm.2004.11.037
pubmed: 15725564
El Maghraby, G. M., Williamsb, A. C. & Barry, B. W. Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J. Pharm. Pharmacol. 51(10), 1123–1134. https://doi.org/10.1211/0022357991776813 (1999).
doi: 10.1211/0022357991776813
pubmed: 10579683
El Maghraby, G. M., Williamsb, A. C. & Barry, B. W. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J. Pharm. Pharmacol. 53(8), 1069–1077. https://doi.org/10.1211/0022357011776450 (2001).
doi: 10.1211/0022357011776450
pubmed: 11518016
Sultan, A. A., El-Gizawy, S. A., Osman, M. A. & El Maghraby, G. M. Self dispersing mixed micelles forming systems for enhanced dissolution and intestinal permeability of hydrochlorothiazide. Colloids Sur. B Biointerfaces. 149, 206–216. https://doi.org/10.1016/j.colsurfb.2016.10.028 (2017).
doi: 10.1016/j.colsurfb.2016.10.028
Elewa, S. H., Osman, M. A., Essa, E. A. & Sultan, A. A. Intestinal absorption pathways of lisinopril: Mechanistic investigations. Biopharm. Drug Dispos. 43(6), 233–246. https://doi.org/10.1002/bdd.2336 (2022).
doi: 10.1002/bdd.2336
pubmed: 36299167
Harwood, M. D., Zhang, M., Pathak, S. M. & Neuhoff, S. The regional-specific relative and absolute expression of gut transporters in adult caucasians: A meta-analysis. Drug Metab. Dispos. 47(8), 854–864. https://doi.org/10.1124/dmd.119.086959 (2019).
doi: 10.1124/dmd.119.086959
pubmed: 31076413
Yin, J. et al. Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K. Am. J. Physiol. Renal Physiol. 317(4), 805–814. https://doi.org/10.1152/ajprenal.00141.2019 (2019).
doi: 10.1152/ajprenal.00141.2019
Jadon, P. S., Gajbhiye, V., Jadon, R. S., Gajbhiye, K. R. & Ganesh, N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS Pharm. Sci. Tech. 10(4), 1186–1192. https://doi.org/10.1208/s12249-009-9325-z (2009).
doi: 10.1208/s12249-009-9325-z
Bansal, S., Aggarwal, G., Chandel, P. & Harikumar, S. L. Design and development of cefdinir niosomes for oral delivery. J. Pharm. Bioallied. Sci. 5(4), 318–325. https://doi.org/10.4103/0975-7406.120080 (2013).
doi: 10.4103/0975-7406.120080
pubmed: 24302841
pmcid: 3831746
Fidan-Yardimci, M. et al. A novel niosome formulation for encapsulation of anthocyanins and modelling intestinal transport. Food Chem. 293, 57–65. https://doi.org/10.1016/j.foodchem.2019.04.086 (2019).
doi: 10.1016/j.foodchem.2019.04.086
pubmed: 31151649
Song, Q. et al. Enhanced uptake and transport of (+)-catechin and (−)-epigallocatechin gallate in niosomal formulation by human intestinal Caco-2 cells. Int. J. Nanomedicine. 9, 2157–2165. https://doi.org/10.2147/IJN.S59331 (2014).
doi: 10.2147/IJN.S59331
pubmed: 24855353
pmcid: 4020900
Porter, C. J., Pouton, C. W., Cuine, J. F. & Charman, W. N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60(6), 673–691. https://doi.org/10.1016/j.addr.2007.10.014 (2008).
doi: 10.1016/j.addr.2007.10.014
pubmed: 18155801
Porter, C., Trevaskis, N. & Charman, W. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6, 231–248. https://doi.org/10.1038/nrd2197 (2007).
doi: 10.1038/nrd2197
pubmed: 17330072
Kalepu, S., Manthina, M. & Padavala, V. Oral lipid-based drug delivery systems—An overview. Acta Pharm. Sin B. 3(6), 361–372. https://doi.org/10.1016/j.apsb.2013.10.001 (2013).
doi: 10.1016/j.apsb.2013.10.001
Manca, M. L. et al. Nanoincorporation of curcumin in polymerglycerosomes and evaluation of their in vitro–in vivo suitability as pulmonary delivery systems. RSC Adv. 5, 105149–105159. https://doi.org/10.1039/C5RA24032H (2015).
doi: 10.1039/C5RA24032H
Gupta, P., Mazumder, R. & Padhi, S. Development of natamycin loaded glycerosomes–A novel approach to defend ophthalmic keratitis. Ind. J. Pharm. Edu. Res. 54(2), 163–172. https://doi.org/10.5530/ijper.54.2s.72 (2020).
doi: 10.5530/ijper.54.2s.72
Zaki, M. R. et al. Central composite optimization of glycerosomes for the enhanced oral bioavailability and brain delivery of quetiapine fumarate. Pharmaceuticals. 15(8), 940. https://doi.org/10.3390/ph15080940 (2022).
doi: 10.3390/ph15080940
pubmed: 36015089
pmcid: 9412614